76
|
Lamidi S, Williams KM, Hind D, Peckham-Cooper A, Miller AS, Smith AM, Saha A, Macutkiewicz C, Griffiths EA, Catena F, Coccolini F, Toogood G, Tierney GM, Boyd-Carson H, Sartelli M, Blencowe NS, Lockwood S, Coe PO, Lee MJ, Barreto SG, Drake T, Gachabayov M, Hill J, Ioannidis O, Lostoridis E, Mehraj A, Negoi I, Pata F, Steenkamp C, Ahmed S, Alin V, Al-Rashedy M, Atici SD, Bains L, Bandyopadhyay SK, Baraket O, Bates T, Beral D, Brown L, Buonomo L, Burke D, Caravaglios G, Ceresoli M, Chapman SJ, Cillara N, Clarke R, Colak E, Daniels S, Demetrashvili Z, Di Carlo I, Duff S, Dziakova J, Elliott JA, El Zalabany T, Engledow A, Ewnte B, Fraga GP, George R, Giuffrida M, Glasbey J, Isik A, Kechagias A, Kenington C, Kessel B, Khokha V, Kong V, Laloë P, Litvin A, Lostoridis E, Marinis A, Martínez-Pérez A, Menzies D, Mills R, Monzon BI, Morgan R, Neri V, Nita GE, Perra T, Perrone G, Porcu A, Poskus T, Premnath S, Sall I, Sarma DR, Slavchev M, Spence G, Tarasconi A, Tolonen M, Toro A, Venn ML, Vimalachandran D, Wheldon L, Zakaria AD. Defining core patient descriptors for perforated peptic ulcer research: international Delphi. Br J Surg 2022; 109:603-609. [PMID: 35467718 DOI: 10.1093/bjs/znac096] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/01/2021] [Revised: 02/09/2022] [Accepted: 03/08/2022] [Indexed: 10/13/2023]
Abstract
BACKGROUND Perforated peptic ulcer (PPU) remains a common condition globally with significant morbidity and mortality. Previous work has demonstrated variation in reporting of patient characteristics in PPU studies, making comparison of studies and outcomes difficult. The aim of this study was to standardize the reporting of patient characteristics, by creating a core descriptor set (CDS) of important descriptors that should be consistently reported in PPU research. METHODS Candidate descriptors were identified through systematic review and stakeholder proposals. An international Delphi exercise involving three survey rounds was undertaken to obtain consensus on key patient characteristics for future research. Participants rated items on a scale of 1-9 with respect to their importance. Items meeting a predetermined threshold (rated 7-9 by over 70 per cent of stakeholders) were included in the final set and ratified at a consensus meeting. Feedback was provided between rounds to allow refinement of ratings. RESULTS Some 116 clinicians were recruited from 29 countries. A total of 63 descriptors were longlisted from the literature, and 27 were proposed by stakeholders. After three survey rounds and a consensus meeting, 27 descriptors were included in the CDS. These covered demographic variables and co-morbidities, risk factors for PPU, presentation and pathway factors, need for organ support, biochemical parameters, prognostic tools, perforation details, and surgical history. CONCLUSION This study defines the core descriptive items for PPU research, which will allow more robust synthesis of studies.
Collapse
|
77
|
Rackimuthu S, Ahmed S, Ishwara PRP, Richie AJ, Colaco KVC. Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL) masquerading as CNS demyelination. THE EGYPTIAN JOURNAL OF NEUROLOGY, PSYCHIATRY AND NEUROSURGERY 2022. [DOI: 10.1186/s41983-022-00502-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022] Open
Abstract
Abstract
Background
CADASIL is the most common single-gene disorder causing ischemic stroke. CADASIL has been linked to mutations in NOTCH3 gene, due to heterozygous missense mutations. The disease is of insidious onset, presenting with initial clinical features in third and fourth decade of life. However, it is now being increasingly acknowledged that individual clinical presentation, age, time of onset as well as disease severity are quite varied among patients with CADASIL most likely leading to under- or mis-diagnosis. The authors thereby report a genetically confirmed case of CADASIL with atypical clinical course and findings.
Case presentation
A 48-year-old woman presented with complaints of episodic headache, relapsing–remitting neurological illness, progressive cognitive impairment, and acute-onset loss of speech and ambulation. She was earlier being treated as a case of CNS demyelination for 10 years. On examination, vital parameters were within normal limits. Neurological examination revealed that the patient was drowsy, not verbalizing, not obeying commands, with movement of all four limbs on painful stimuli, hypertonia of all limbs, grade 3 + deep tendon reflexes, bilateral striatal toe and extensor plantar response. Magnetic resonance imaging of brain showed involvement of anterior temporal lobe and external capsule along with multiple acute infarcts. Cerebrospinal fluid analysis was found to be normal. Exome sequencing revealed heterozygous missense mutation in exon 2 of NOTCH3 gene. A definite diagnosis of CADASIL was made and patient was started on fluoxetine and aspirin, following which there was significant improvement over 4–6 weeks. Patient is able to carry out daily activities independently although continues to have mild persistent cognitive impairment with excessive talking and over familiarity.
Conclusions
As CADASIL has a relapsing and partially remitting course with frequently observed varied clinical presentation, patients may receive treatment for demyelination which may not be necessary. Hence, detailed family history along with knowledge of characteristic magnetic resonance imaging findings seen in CADASIL can help discern the diagnosis.
Collapse
|
78
|
Gupta L, Pakhchanian H, Khan H, Raiker R, Abbasi M, Deyoung C, Kardes S, Ahmed S, Kavadichanda C, Sen P, Aggarwal R. POS0198 COVID-19 OUTCOMES IN PATIENTS WITH DERMATOMYOSITIS: A REGISTRY-BASED COHORT ANALYSIS. Ann Rheum Dis 2022. [DOI: 10.1136/annrheumdis-2022-eular.4695] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
Abstract
BackgroundDermatomyositis (DM) patients have fewer risks of COVID-19 infection compared to the general population, however, certain subgroups with DM have worse outcomes. Men. African Americans, those with interstitial lung disease, exhibited higher risks of severe COVID-19. DMARD and glucocorticoid use was associated with frequent hospitalisations and severe sepsis.ObjectivesRheumatic diseases (RDs) like DM, are previously known to be vulnerable towards various types of infections due to its aggressive activity mandating high dose immunosuppressive therapy. The severity of COVID-19 in RDs is limited in literature due to the heterogeneous nature of the condition. Therefore, specific details on mortality is essential to navigate any precautions required in the treatment.MethodsRetrospective data of individuals with DM and COVID-19 and the general population with COVID-19 between January 2020 to August 2020 was retrieved from the TriNetX database. A one-to-one matched COVID-19 positive control was selected using propensity score (PS) matching. We assessed COVID-19 outcomes such as mortality, hospitalisation, ICU admission, severe COVID-19, mechanical ventilation (MV), acute kidney injury (AKI), venous thromboembolism (VTE), ischemic stroke, acute respiratory distress syndrome (ARDS), renal replacement therapy (RRT) and sepsis. Subgroup analyses included gender, race, ILD, cancer patients, disease-modifying rheumatic drugs (DMARDs) use, and glucocorticoids (GC) use (Figure 1).Figure 1.Overview of studyResultsWe identified 5,574 DM patients with COVID-19, and 5,574 general population with COVID-19 (controls). DM with COVID-19 had a lower risk of mortality in comparison to controls [RR 0.76], hospitalisation [RR 0.8], severe COVID-19 [RR 0.76], AKI [RR 0.83], and sepsis [RR 0.73]. Males and African Americans were more likely to develop AKI [RR 1.35, 1.65], while African Americans had higher odds for severe COVID-19 [RR 1.62] and VTE [RR 1.54]. DM with ILD group also experienced higher odds for severe COVID-19 infection [RR 1.64], and VTE [RR 2.06] (Figure 1).DM patients receiving DMARDs and glucocorticoids had higher odds for hospitalisation [RR 1.46, 2.12], and sepsis [RR 3.25] Subgroup analysis of neoplasms amongst DM patients with COVID-19 was inadequate for meaningful comparison (Figure 1).ConclusionDM patients are protected for certain aspects of COVID-19 disease, including severe COVID-19, hospitalization, and mortality. The African American race, male gender, ILD, DMARDS and glucocorticoid users, are associated with poor outcomes.Disclosure of InterestsLatika Gupta: None declared, Haig Pakhchanian: None declared, Hiba Khan: None declared, Rahul Raiker: None declared, Maryam Abbasi: None declared, Charles DeYoung: None declared, Sinan Kardes Grant/research support from: SK has received congress travel, accommodation, and participation fee support (12th Anatolian Rheumatology Days) from Abbvie, Sakir Ahmed Speakers bureau: SA has received honorarium as speaker for Pfizer, Chengappa Kavadichanda: None declared, Parikshit Sen: None declared, Rohit Aggarwal Consultant of: RA has/had a consultancy relationship with and/or has received research funding from the following companies-Bristol Myers-Squibb, Pfizer, Genentech, Octapharma, CSL Behring, Mallinckrodt, AstraZeneca, Corbus, Kezar, and Abbvie, Janssen, Alexion, Argenx, Q32, EMD-Serono, Boehringer Ingelheim, Roivant., Grant/research support from: RA has/had a consultancy relationship with and/or has received research funding from the following companies-Bristol Myers-Squibb, Pfizer, Genentech, Octapharma, CSL Behring, Mallinckrodt, AstraZeneca, Corbus, Kezar, and Abbvie, Janssen, Alexion, Argenx, Q32, EMD-Serono, Boehringer Ingelheim, Roivant.
Collapse
|
79
|
Javad S, Shah AA, Ramzan M, Sardar R, Javed T, Al-Huqail AA, Ali HM, Chaudhry O, Yasin NA, Ahmed S, Hussain RA, Hussain I. Hydrogen sulphide alleviates cadmium stress in Trigonella foenum-graecum by modulating antioxidant enzymes and polyamine content. PLANT BIOLOGY (STUTTGART, GERMANY) 2022; 24:618-626. [PMID: 35114051 DOI: 10.1111/plb.13393] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 11/08/2021] [Accepted: 01/06/2022] [Indexed: 05/02/2023]
Abstract
Cadmium (Cd) toxicity reduces growth and yield of crops grown in metal-polluted sites. Research was conducted to estimate the potential of hydrogen sulphide (H2 S) to mitigate toxicity caused by Cd in fenugreek seedlings (Trigonella foenum-graecum L.). Different concentrations of CdCl2 (Cd1-1 mM, Cd2-1.5 mM, Cd3-2mM) and H2 S (HS1-100 µM, HS2-150 µM, HS3-200 µM) were assessed. Seeds of fenugreek were primed with sodium hydrosulphide (NaHS), as H2 S donor. Seedlings growing in Cd-spiked media treated with H2 S were harvested after 2 weeks. Cd stress affected growth of fenugreek seedlings. Cd toxicity decreased leaf relative water content (LRWC), intercellular CO2 concentration, net photosynthesis, stomatal conductance and transpiration. However, application of H2 S significantly improved seedling morphological attributes by increasing the activity of antioxidant enzymes, i.e. APX, CAT and SOD, in Cd-contaminated soil. H2 S treatment also regulated phenolic and flavonoid content. H2 S-induced biosynthesis of spermidine (Spd) and putrescine (Put) could account for the enhancement of growth and physiological performance of fenugreek seedlings under Cd stress. H2 S treatment also reduced H2 O2 production (38%) and electrolyte leakage (EL, 51%) in seedlings grown in different concentrations of Cd. It is recommended to evaluate the efficacy of H2 S in alleviating Cd toxicity in other crop plants.
Collapse
|
80
|
Ablikim M, Achasov MN, Adlarson P, Ahmed S, Albrecht M, Aliberti R, Amoroso A, An MR, An Q, Bai XH, Bai Y, Bakina O, Baldini Ferroli R, Balossino I, Ban Y, Begzsuren K, Berger N, Bertani M, Bettoni D, Bianchi F, Biernat J, Bloms J, Bortone A, Boyko I, Briere RA, Cai H, Cai X, Calcaterra A, Cao GF, Cao N, Cetin SA, Chang JF, Chang WL, Chelkov G, Chen DY, Chen G, Chen HS, Chen ML, Chen SJ, Chen XR, Chen YB, Chen ZJ, Cheng WS, Cibinetto G, Cossio F, Cui XF, Dai HL, Dai XC, Dbeyssi A, de Boer RE, Dedovich D, Deng ZY, Denig A, Denysenko I, Destefanis M, De Mori F, Ding Y, Dong C, Dong J, Dong LY, Dong MY, Dong X, Du SX, Fan YL, Fang J, Fang SS, Fang Y, Farinelli R, Fava L, Feldbauer F, Felici G, Feng CQ, Feng JH, Fritsch M, Fu CD, Gao Y, Gao Y, Gao Y, Gao YG, Garzia I, Ge PT, Geng C, Gersabeck EM, Gilman A, Goetzen K, Gong L, Gong WX, Gradl W, Greco M, Gu LM, Gu MH, Gu S, Gu YT, Guan CY, Guo AQ, Guo LB, Guo RP, Guo YP, Guskov A, Han TT, Han WY, Hansson J, Hao XQ, Harris FA, Hüsken N, He KL, Heinsius FH, Heinz CH, Held T, Heng YK, Herold C, Himmelreich M, Holtmann T, Hou YR, Hou ZL, Hu HM, Hu JF, Hu T, Hu Y, Huang GS, Huang LQ, Huang XT, Huang YP, Huang Z, Hussain T, Ikegami Andersson W, Imoehl W, Irshad M, Jaeger S, Janchiv S, Ji Q, Ji QP, Ji XB, Ji XL, Ji YY, Jiang HB, Jiang XS, Jiao JB, Jiao Z, Jin S, Jin Y, Johansson T, Kalantar-Nayestanaki N, Kang XS, Kappert R, Kavatsyuk M, Ke BC, Keshk IK, Khoukaz A, Kiese P, Kiuchi R, Kliemt R, Koch L, Kolcu OB, Kopf B, Kuemmel M, Kuessner M, Kupsc A, Kurth MG, Kühn W, Lane JJ, Lange JS, Larin P, Lavania A, Lavezzi L, Lei ZH, Leithoff H, Lellmann M, Lenz T, Li C, Li CH, Li C, Li DM, Li F, Li G, Li H, Li H, Li HB, Li HJ, Li HJ, Li JL, Li JQ, Li JS, Li K, Li LK, Li L, Li PR, Li SY, Li WD, Li WG, Li XH, Li XL, Li X, Li ZY, Liang H, Liang H, Liang H, Liang YF, Liang YT, Liao GR, Liao LZ, Libby J, Lin CX, Liu BJ, Liu CX, Liu D, Liu FH, Liu F, Liu F, Liu HB, Liu HM, Liu H, Liu H, Liu JB, Liu JL, Liu JY, Liu K, Liu KY, Liu K, Liu L, Liu MH, Liu PL, Liu Q, Liu Q, Liu SB, Liu S, Liu T, Liu WM, Liu X, Liu Y, Liu YB, Liu ZA, Liu ZQ, Lou XC, Lu FX, Lu FX, Lu HJ, Lu JD, Lu JG, Lu XL, Lu Y, Lu YP, Luo CL, Luo MX, Luo PW, Luo T, Luo XL, Lusso S, Lyu XR, Ma FC, Ma HL, Ma LL, Ma MM, Ma QM, Ma RQ, Ma RT, Ma XX, Ma XY, Maas FE, Maggiora M, Maldaner S, Malde S, Malik QA, Mangoni A, Mao YJ, Mao ZP, Marcello S, Meng ZX, Messchendorp JG, Mezzadri G, Min TJ, Mitchell RE, Mo XH, Mo YJ, Muchnoi NY, Muramatsu H, Nakhoul S, Nefedov Y, Nerling F, Nikolaev IB, Ning Z, Nisar S, Olsen SL, Ouyang Q, Pacetti S, Pan X, Pan Y, Pathak A, Patteri P, Pelizaeus M, Peng HP, Peters K, Ping JL, Ping RG, Poling R, Prasad V, Qi H, Qi HR, Qi KH, Qi M, Qi TY, Qi TY, Qian S, Qian WB, Qian Z, Qiao CF, Qin LQ, Qin XP, Qin XS, Qin ZH, Qiu JF, Qu SQ, Rashid KH, Ravindran K, Redmer CF, Rivetti A, Rodin V, Rolo M, Rong G, Rosner C, Rump M, Sang HS, Sarantsev A, Schelhaas Y, Schnier C, Schönning K, Scodeggio M, Shan DC, Shan W, Shan XY, Shangguan JF, Shao M, Shen CP, Shen PX, Shen XY, Shi HC, Shi RS, Shi X, Shi XD, Song JJ, Song WM, Song YX, Sosio S, Spataro S, Su KX, Su PP, Sui FF, Sun GX, Sun HK, Sun JF, Sun L, Sun SS, Sun T, Sun WY, Sun WY, Sun X, Sun YJ, Sun YK, Sun YZ, Sun ZT, Tan YH, Tan YX, Tang CJ, Tang GY, Tang J, Teng JX, Thoren V, Tian YT, Uman I, Wang B, Wang CW, Wang DY, Wang HJ, Wang HP, Wang K, Wang LL, Wang M, Wang MZ, Wang M, Wang W, Wang WH, Wang WP, Wang X, Wang XF, Wang XL, Wang Y, Wang Y, Wang YD, Wang YF, Wang YQ, Wang YY, Wang Z, Wang ZY, Wang Z, Wang Z, Wei DH, Weidenkaff P, Weidner F, Wen SP, White DJ, Wiedner U, Wilkinson G, Wolke M, Wollenberg L, Wu JF, Wu LH, Wu LJ, Wu X, Wu Z, Xia L, Xiao H, Xiao SY, Xiao ZJ, Xie XH, Xie YG, Xie YH, Xing TY, Xu GF, Xu QJ, Xu W, Xu XP, Xu YC, Yan F, Yan L, Yan WB, Yan WC, Yan X, Yang HJ, Yang HX, Yang L, Yang SL, Yang YX, Yang Y, Yang Z, Ye M, Ye MH, Yin JH, You ZY, Yu BX, Yu CX, Yu G, Yu JS, Yu T, Yuan CZ, Yuan L, Yuan XQ, Yuan Y, Yuan ZY, Yue CX, Zafar AA, Zeng Y, Zhang BX, Zhang G, Zhang H, Zhang HH, Zhang HH, Zhang HY, Zhang JJ, Zhang JL, Zhang JQ, Zhang JW, Zhang JY, Zhang JZ, Zhang J, Zhang J, Zhang LM, Zhang LQ, Zhang L, Zhang S, Zhang SF, Zhang S, Zhang XD, Zhang XY, Zhang Y, Zhang YH, Zhang YT, Zhang Y, Zhang Y, Zhang Y, Zhang ZH, Zhang ZY, Zhao G, Zhao J, Zhao JY, Zhao JZ, Zhao L, Zhao L, Zhao MG, Zhao Q, Zhao SJ, Zhao YB, Zhao YX, Zhao ZG, Zhemchugov A, Zheng B, Zheng JP, Zheng Y, Zheng YH, Zhong B, Zhong C, Zhou LP, Zhou Q, Zhou X, Zhou XK, Zhou XR, Zhou XY, Zhu AN, Zhu J, Zhu K, Zhu KJ, Zhu SH, Zhu TJ, Zhu WJ, Zhu WJ, Zhu YC, Zhu ZA, Zou BS, Zou JH. Probing CP symmetry and weak phases with entangled double-strange baryons. Nature 2022; 606:64-69. [PMID: 35650355 PMCID: PMC9159954 DOI: 10.1038/s41586-022-04624-1] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/20/2021] [Accepted: 03/08/2022] [Indexed: 12/03/2022]
Abstract
Though immensely successful, the standard model of particle physics does not offer any explanation as to why our Universe contains so much more matter than antimatter. A key to a dynamically generated matter-antimatter asymmetry is the existence of processes that violate the combined charge conjugation and parity (CP) symmetry1. As such, precision tests of CP symmetry may be used to search for physics beyond the standard model. However, hadrons decay through an interplay of strong and weak processes, quantified in terms of relative phases between the amplitudes. Although previous experiments constructed CP observables that depend on both strong and weak phases, we present an approach where sequential two-body decays of entangled multi-strange baryon-antibaryon pairs provide a separation between these phases. Our method, exploiting spin entanglement between the double-strange Ξ- baryon and its antiparticle2 [Formula: see text], has enabled a direct determination of the weak-phase difference, (ξP - ξS) = (1.2 ± 3.4 ± 0.8) × 10-2 rad. Furthermore, three independent CP observables can be constructed from our measured parameters. The precision in the estimated parameters for a given data sample size is several orders of magnitude greater than achieved with previous methods3. Finally, we provide an independent measurement of the recently debated Λ decay parameter αΛ (refs. 4,5). The [Formula: see text] asymmetry is in agreement with and compatible in precision to the most precise previous measurement4.
Collapse
|
81
|
Liem S, Ahmed S, Ciaffi J, Beaart- van de Voorde L, Schouffoer A, Geelhoed J, Ajmone-Marsan N, Huizinga T, De Vries-Bouwstra J. POS0916 A 10-YEAR JOURNEY OF CARING FOR PATIENTS WITH SYSTEMIC SCLEROSIS: FOLLOW-UP DATA ON DISEASE DURATION OF THE LEIDEN CCISS COHORT. Ann Rheum Dis 2022. [DOI: 10.1136/annrheumdis-2022-eular.4339] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
Abstract
BackgroundCombined Care in Systemic Sclerosis (CCISS) is a prospective cohort of patients referred to Leiden University Medical Center for Raynaud’s Phenomenon (RP), a suspicion of systemic sclerosis (SSc) or a connective tissue disease. This cohort is characterized by its standardized and extensive annual follow-up. Since initiation of the cohort in 2009, diagnostic criteria for SSc have been updated leading to a higher sensitivity for early SSc (ACR 2013 criteria). A recent Dutch study showed that there is a gap to time of diagnosis between men and women, despite of overall increase of SSc awareness (PMID: 31539063).ObjectivesTo determine whether 1. time between first disease symptoms and diagnosis has changed over time, and 2. disease characteristics of SSc at first presentation in an expert clinic have changed over time for the total cohort, and between male and female patients.MethodsPatients included in the CCISS cohort undergo annual evaluation and clinical, laboratory, and imaging variables are systematically recorded. For this study, patients fulfilling the ACR/EULAR 2013 SSc criteria were included, and categorized into three groups based on the cohort entrance year: 1) 2010 – 2013, 2) 2014 – 2017, and 3) 2018 – 2021. SSc patients with a baseline visit in 2009 (n=65) were excluded as these patients were often not newly referred. Disease duration was defined by months since first RP, since first non-RP symptom and months between first date of diagnosis by a physician and first non-RP symptom. Disease characteristics included presence of interstitial lung disease (ILD), pulmonary arterial hypertension, digital ulcers (DU), diffuse cutaneous SSc, anti-topoisomerase and anticentromere antibodies. At baseline, disease duration and disease characteristics were compared between the three groups using appropriate tests. In addition, disease duration was compared between males and females in the three groups.ResultsIn total, 643 SSc patients were included of whom 229 (36%) had their baseline visit from 2010 until 2013, 207 (32%) from 2014 until 2017, and 207 (32%) from 2018 until 2021.The proportion of female patients was significantly higher in the 2010 – 2013 group compared to the 2014 – 2017 and 2018 – 2021 group (Table 1). Over time, disease duration defined by RP duration and non-RP duration decreased as well as time between diagnosis and first non-RP symptom (Table 1). The proportion of patients presenting with ILD and DU was highest in the first group (Table 1).Table 1.2010 - 2013 N=2292014- 2017 N=2072018 – 2021 N=207P-valueBASELINEAge, mean (SD)53 (15)57 (14)55 (14)0.003Female, %8676750.010RP duration, months (IQR)122 (46 – 240)93 (20 – 202)67 (20 – 210)0.003Non RP duration, months (IQR)43 (16 – 227)20 (5 – 112)17 (6 – 54)<0.001Diagnosis duration, months (IQR)116 (80 - 177)65 (45 – 105)25 (5 – 45)<0.001ΔRP and Non-RP, months (IQR)24 (0 – 99)18 (0 – 118)22 (0 – 120)0.337Anti-centromere antibodies, %3843490.092Anti-topoisomerase antibodies, %2424180.259Diffuse cutaneous SSc, %1923160.073Interstitial lung disease, %433131<0.001Pulmonary arterial hypertension, %3240.746Digital ulcers, %2013110.041In both male and female SSc patients, disease duration and time between diagnosis and first non-RP decreased over time with a longer time in females for all durations which was significantly different for time between first RP and non-RP in 2014-2017 and 2018-2021 (Figure 1). For the 2018 – 2021 group, duration since diagnosis for female was 26 (4 - 46) and male 17 months (7 – 39; p=0.355), and time between RP and non-RP for female 24 (0 - 168) and male 12 months (0 – 48; p=0.029).Figure 1.ConclusionOver time, we observe a decrease in disease duration and in SSc patients presenting with ILD or DU at cohort entrance. Our results indicate increased awareness of early SSc and identification of SSc patients before severe complications have occurred. At the same time our results show the urge for specific attention to improve timely diagnosis in female SSc patients.Disclosure of InterestsNone declared
Collapse
|
82
|
Ahmed S, Rashid Y, Jabbar A. P-251 Outcomes in patients with locally advanced esophageal cancer after neoadjuvant concurrent chemoradiation: A retrospective study from low- to middle-income countries. Ann Oncol 2022. [DOI: 10.1016/j.annonc.2022.04.341] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/01/2022] Open
|
83
|
Sreekanth A, Skaria T, Joseph S, Umesh R, Mohanan M, Paul A, Ahmed S, Mehta P, Oomen S, Benny J, George J, Paulose A, Narayanan K, Joseph S, Vijayan A, Nalianda K, Shenoy P. LB0003 WITHDRAWING METHOTREXATE AFTER BOTH VERSUS ONLY SECOND DOSE OF THE ChAdOx1 nCoV-19 VACCINE IN PATIENTS WITH AUTOIMMUNE INFLAMMATORY ARTHRITIS: TWO INDEPENDENT RANDOMIZED CONTROLLED TRIALS (MIVAC I AND II). Ann Rheum Dis 2022. [DOI: 10.1136/annrheumdis-2022-eular.5121a] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
Abstract
BackgroundPausing methotrexate (MTX) for two to four weeks, improved immunogenicity of influenza vaccination in patients with rheumatoid arthritis (RA), albeit a risk of disease flare (1). This guided the framing of guidelines on MTX withdrawal for COVID-19 vaccination (2). However, evidence for MTX withdrawal for COVID-19 vaccination is limited to observational studies only.ObjectivesTo compare the efficacy and safety of holding MTX after each (MIVAC 1) and only after the second dose (MIVAC II) of the ChAdOx1 vaccine versus continuation of MTX in two randomized controlled trials (RCTs).MethodsTwo single centre, investigator-blinded, RCTs were conducted in patients with RA or Psoriatic arthritis (PsA) on stable doses of MTX without prior COVID-19 (CTRI reg. no. MIVAC I: CTRI/2021/07/03463 & MIVAC II: CTRI/2021/07/035307). In MIVAC I, unvaccinated patients were randomised (1:1) to hold or continue MTX for two weeks after each dose of the vaccine. MIVAC II included patients who had continued MTX during the first dose of ChAdOx1 and were randomised (1:1) to hold or continue MTX for 2 weeks after the second vaccine dose. The primary outcome for both the trials was the anti-Receptor Binding Domain (RBD) antibody titres measured four weeks after the second vaccine dose (per protocol analysis). Secondary outcome was the flare rate, defined as an increase in disease activity scores (DAS28/cDAPSA) or physician intent to hike DMARDs.Results250 patients were randomized for MIVAC 1 and 178 for MIVAC II and after due exclusions, 158 and 157 were eligible for analysis respectively (Figure 1). In MIVAC I, median anti-RBD titres were significantly high in the MTX hold group [2484 (1050-4388) versus 1147(433-2360), p=0.001] but the flare rate was higher in the hold group [20 (25%) versus 6(8%) p=0.005] compared to continue group. In MIVAC II median anti-RBD titres were significantly high for the MTX hold group [2553 (1792-4823) versus 990 (356-2252), p=0.001] when compared to continue group but there was no difference in the flare rate between the groups [9(11.8%) and 4(7.9%), p=0.15] (Table 1). Since both were parallel studies in similar population, MTX hold arms across both the trials were compared for anti-RBD titres and flare. There was no difference in the anti-RBD titres [p=0.2] between the groups. In MIVAC I, 29(36.25%) patients had reported flare (19 in either first or second dose, 10 for both doses) when compared to MIVAC II where only 9(11.84%) patients had reported flare after the second dose (P <0.001).Table 1.Baseline demographics and key resultsVariableMIVAC IMIVAC IIMTX HoldMTX ContinuePMTX HoldMTX ContinueP valueN=80N=78valueN=76N=81Age†48 (38-53.3)49 (39-59)0.1953 (42.3-59)53(50-62)0.14Female (%) ‡73 (91.3)75 (96.2)0.3365 (85.5)70 (86.4)>0.99RA (%) ‡69(86.3)69 (93.2)70 (85.6)80 (87.7)PsA (%) ‡11(13.8)6 (8.1)0.316 (7.9)1 (1.2)0.057DAS28†2.7 (2.4-3.2)2.6 (2-3.3)0.62.7(2.3-3.4)2.8 (2.1-3.5)0.78cDAPSA †2(3-4.5)2.5(1.3-3.8)0.463(2.8-3)30.15Prednisolone (%) ‡29 (36.3)23(31.1)0.424(31.6)26 (32.1)>0.99MTX mg/week†17.5 (10-25)15 (10-20)0.05715 (9.4-25)17.5(7.5-25)0.92Anti- RBD antibody titres post second dose (IU/mL) †2484 (1050-4388.8)1147.5 (433.5-2360.3)<0.0012553.5 (1792.5-4823.8)990.5 (356.1-2252.5)<0.001Flare (N%) ‡Post first dose20 (25)6 (8)0.005NANAPost second dose19 (23.8)10(13.3)0.19 (11.8)4 (7.9)0.15All analysis as per protocol population.†Median (interquartile range): Mann Whitney U test.‡ N (%): Fisher Exact test. Bolded if p<0.05.ConclusionHolding MTX after both the doses or only after the second dose of ChAdOx1 yields higher anti-RBD antibody titres as compared to continuing MTX. Comparing across the trials, holding MTX only after the second dose appears to be non-inferior to holding MTX after both doses of the vaccine with a lesser risk of flare.References[1]Park JK et al. Clin Rheumatol. 2020 Feb; 39(2):375-379.[2]Curtis JR, et al. Arthritis & Rheumatology. 2021 Oct;73(10): e60-75.AcknowledgementsAcknowledgments to all participating investigators, patients and their familiesDisclosure of InterestsAnu Sreekanth: None declared, Teny Skaria: None declared, Sneha Joseph: None declared, Rashwith Umesh: None declared, Manju Mohanan: None declared, Aby Paul: None declared, Sakir Ahmed Speakers bureau: Sakir Ahmed had received honorarium as speaker from Pfizer, Dr Reddy’s, Cipla, and Novartis unrelated to this Comment, Pankti Mehta: None declared, Seena Oomen: None declared, Janet Benny: None declared, Justin George: None declared, Anagha Paulose: None declared, K Narayanan: None declared, Sanjana Joseph: None declared, Anuroopa Vijayan: None declared, Kaveri Nalianda: None declared, Padmanabha Shenoy: None declared
Collapse
|
84
|
Malepati NH, Maikap D, Padhan P, Misra R, Cr S, Ahmed S. AB0551 CUTANEOUS LUPUS AREA AND SEVERITY INDEX(CLASI) CORRELATES WITH SELF-IMAGE SCORE BUT NOT QUALITY OF LIFE IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS. Ann Rheum Dis 2022. [DOI: 10.1136/annrheumdis-2022-eular.4361] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
Abstract
BackgroundSystemic lupus erythematosus (SLE) has multi-system involvement including skin. We explored how skin involvement influenced with the quality of life of patients with SLE.ObjectivesTo correlate the domains of SLE QoL with skin involvement and total lupus disease activity.MethodsA cross-sectional survey of patients with SLE was carried out to assess Cutaneous Lupus Erythematosus Disease Area and Severity Index (CLASI) and SLE-QoL. Lupus disease activity and damage were quantified using Mex-SLEDAI (Mexican SLE Disease Activity Index) and SLICC (Systemic Lupus International Collaborating Clinics) Damage Index respectively. Data is expressed as median (IQR).ResultsIn the cohort of 35 patients with SLE, with an age of 26(IQR:17-32) years and including eight (22.8%) males, the CLASI score was 5.5(IQR:3-11.5) with an activity score of 3(1-5) and a chronicity score of 1(0-4). The disease duration was 4years (IQR: 2-3) while SLE-QoL was 73(62-86). Overall, most of the patients had active disease at inclusion with a mex-SLEDAI of 8(6.5-11.5). SLICC was 1(0-4).The correlation matrix of different domains of the SLE-QoL with CLASI, and Mex-SLEDAI is presented in Table 1. Correlation with SLICC was not analysed since it was zero in the majority of participants. Multivariate analyses were not done since there was lack of association on univariate analysis.Table 1.Correlations between different domains of the SLE(Systemic Lupus Erythematosus) -QoL(Quality of Life) with CLASI (Cutaneous Lupus Area and Severity Index) and Mexican SLE-DAI(SLE Disease Activity Index).SLE-QoL DomainsPhysical functioningPhysical activitySymptomsTreatmentMoodSelfimageTotalCLASI Activity.028-.062.242.103.113.252.102(p=0.87)(p=0.73)(p=0.16)(p=0.56)(p=0.52)(p=0.15)(p=0.56)CLASI Damage.125.010.257.239.233.446**.243(p=0.47)(p=0.95)(p=0.13)(p=0.17)(p=0.18)(p=0.007)(p=0.16)CLASI total.047-.062.448*.331.332.315.281(p=0.80)(p=0.75)(p=0.013)(p=0.07)(p=0.07)(p=0.09(p=0.13)Mexican SLEDAI SCORE.001.130.390*.251.115.197.200(p=0.99)(p=0.47)(p=0.025)(p=0.16)(p=0.52)(p=0.27)(p=0.27)ConclusionIn this cohort of patients with active SLE, the SLE-QoL did not correlate with either the overall disease activity score nor the skin specific score. Only the Self-image domain correlated with the skin score. This implies that in active disease, the skin involvement may have only a minor effect on the quality of life.References[1]Klein R, Moghadam-Kia S, LoMonico J, Okawa J, Coley C, Taylor L, Troxel AB, Werth VP. Development of the CLASI as a tool to measure disease severity and responsiveness to therapy in cutaneous lupus erythematosus. Archives of dermatology. 2011 Feb 1;147(2):203-8.[2]Leong KP, Kong KO, Thong BY, Koh ET, Lian TY, Teh CL, Cheng YK, Chng HH, Badsha H, Law WG, Lau TC. Development and preliminary validation of a systemic lupus erythematosus-specific quality-of-life instrument (SLEQOL). Rheumatology. 2005 Oct 1;44(10):1267-76.Disclosure of InterestsNone declared
Collapse
|
85
|
Ahmed S, Relton S, West R, Sandoe J. P19 A service evaluation to assess antimicrobial resistance in penicillin allergy. JAC Antimicrob Resist 2022. [PMCID: PMC9155987 DOI: 10.1093/jacamr/dlac053.019] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Background Antibiotic consumption is one of the main drivers for antimicrobial resistance (AMR). To improve clinical outcomes and tackle AMR, we need to improve antibiotic usage in patients with penicillin allergy (PenA). Patients with PenA have been found to have higher antibiotic usage, often requiring repeated courses of antibiotics compared with those without PenA. Additionally, patients with PenA are more likely to receive broad spectrum antibiotics. Objectives To determine whether patients who have PenA are more likely to be colonized or infected with resistant bacteria. Methods Data were extracted from the pathology reporting system (Telepath) for blood culture specimens isolating Staphylococcus aureus and Streptococcus pneumoniae between 2017 and 2019 at Leeds Teaching Hospitals NHS Trust. Sputum samples from 2019 that isolated S. pneumoniae and Haemophilus influenzae were also analysed. These organisms/samples were chosen as these would indicate the presence of an infection where a penicillin would normally be used as first-line therapy. Where patients had multiple samples only the first sample obtained during the study period was included in the analysis. Standard descriptive statistics was used to summarize the data and characteristics were cross tabulated with penicillin allergy status. Results S. pneumoniae isolated from blood cultures: A total of 297 patients were included in the analysis, 33/297 (11.1%) had PenA, 50.8% were female and the median age was 60 years (IQR 37–75). Susceptibility results are summarized in Figure 1. Resistant isolates are comprised of isolates with resistant or intermediate susceptibility. S. aureus isolated from blood cultures: Analysis included 783 isolates from first patient encounters, 97/783 (12.4%) patients had PenA, 35.1% were female and the median age was 58 years (IQR 39–74.5). Susceptibility results are summarized in Figure 2. S. pneumoniae isolated from sputum: A total of 156 isolates were included in the final analysis: 29/156 (18.6%) patients had PenA, 53.3% were female and the median age was 67 years. Susceptibility results are summarized in Figure 3. H. influenzae isolated from sputum: A total 719 samples were included, 122/719 (15.8%) patients had PenA, 55.9% were female and median age was 67 years. Susceptibility results are summarized in Figure 4. Conclusions PenA prevalence differs across different patient populations. A higher proportion of patients with PenA had resistance in S. pneumoniae sputum isolates compared with those without, however this finding did not meet statistical significance. Further studies evaluating the impact of PenA on AMR need to be conducted.
Collapse
|
86
|
Hashmi S, Jafri L, Majid H, Khan A, Ahmed S. W219 Lysine protein intolerance – Clinicopathological spectrum of a rare disease. Clin Chim Acta 2022. [DOI: 10.1016/j.cca.2022.04.423] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
|
87
|
Hindocha S, Charlton T, Linton-Reid K, Hunter B, Chan C, Ahmed M, Robinson E, Orton M, Lunn J, Ahmed S, McDonald F, Locke I, Power D, Doran S, Blackledge M, Lee R, Aboagye E. MO-0384 A CT-radiomics model to predict recurrence post curative-intent radiotherapy for stage I-III NSCLC. Radiother Oncol 2022. [DOI: 10.1016/s0167-8140(22)02350-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
|
88
|
Gjini M, Brodin P, Ahmed S, Tomé W, Kalnicki S, Guha C, Kabarriti R, Garg M. PD-0824 Parotid gland volumetric change during IMRT and implications for stem cell sparing strategies. Radiother Oncol 2022. [DOI: 10.1016/s0167-8140(22)02965-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
89
|
van Dijk L, Ahmed S, Mohammed A, Wahid K, Sijtsema N, Gunn B, Garden A, Langendijk J, Fuller C. OC-0755 Big data prediction models to select head and neck patients for personalized dose prescription. Radiother Oncol 2022. [DOI: 10.1016/s0167-8140(22)02661-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
90
|
Shakeel S, Ahmed S, Jafri L, Ahmed S, Khan A. T116 Performance evaluation of a point-of-care testing program operational at 30 sites with six sigma metrics – Experience from a tertiary care hospital in Pakistan. Clin Chim Acta 2022. [DOI: 10.1016/j.cca.2022.04.584] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
91
|
Varsani J, Tsang Y, Nunes S, Ahmed S, Newton V, Westbury C. OC-0950 Dosimetric comparisons of wide tangent and VMAT techniques in breast IMC radiotherapy. Radiother Oncol 2022. [DOI: 10.1016/s0167-8140(22)02730-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
|
92
|
Majid H, Jafri L, Ahmed S, Khan A. W006 Neurological deficit at the time of presentation in patients with maple syrup urine disease: A single centre point prevalence study. Clin Chim Acta 2022. [DOI: 10.1016/j.cca.2022.04.136] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
93
|
Kausar R, Jafri L, Khan A, Ahmed S. W020 Performance evaluation and diagnostic accuracy of anti phospholipase A2 receptor (PLA2R) IGG for the diagnosis of primary membranous nephropathy – Experience from a clinical laboratory in Pakistan. Clin Chim Acta 2022. [DOI: 10.1016/j.cca.2022.04.151] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
94
|
Bano N, Hashmi S, Jafri L, Siddiqui I, Ahmed S. M154 Performance evaluation of a chemiluminescence (CLIA) immunoassay for quantification of aldosterone- a step towards continuous quality improvement. Clin Chim Acta 2022. [DOI: 10.1016/j.cca.2022.04.036] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
|
95
|
Ablikim M, Achasov M, Adlarson P, Ahmed S, Albrecht M, Aliberti R, Amoroso A, An M, An Q, Bai X, Bai Y, Bakina O, Baldini Ferroli R, Balossino I, Ban Y, Begzsuren K, Berger N, Bertani M, Bettoni D, Bianchi F, Bloms J, Bortone A, Boyko I, Briere R, Cai H, Cai X, Calcaterra A, Cao G, Cao N, Cetin S, Chang J, Chang W, Chelkov G, Chen D, Chen G, Chen H, Chen M, Chen S, Chen X, Chen Y, Chen Z, Cheng W, Cibinetto G, Cossio F, Cui X, Dai H, Dai J, Dai X, Dbeyssi A, de Boer R, Dedovich D, Deng Z, Denig A, Denysenko I, Destefanis M, De Mori F, Ding Y, Dong C, Dong J, Dong L, Dong M, Dong X, Du S, Egorov P, Fan Y, Fang J, Fang S, Fang Y, Farinelli R, Fava L, Feldbauer F, Felici G, Feng C, Feng J, Fritsch M, Fu C, Gao Y, Gao Y, Gao Y, Garzia I, Ge P, Geng C, Gersabeck E, Gilman A, Goetzen K, Gong L, Gong W, Gradl W, Greco M, Gu L, Gu M, Guan C, Guo A, Guo A, Guo L, Guo R, Guo Y, Guskov A, Han T, Han W, Hao X, Harris F, He K, He K, Heinsius F, Heinz C, Heng Y, Herold C, Himmelreich M, Holtmann T, Hou G, Hou Y, Hou Z, Hu H, Hu J, Hu T, Hu Y, Huang G, Huang L, Huang X, Huang Y, Huang Z, Hussain T, Hüsken N, Ikegami Andersson W, Imoehl W, Irshad M, Jaeger S, Janchiv S, Ji Q, Ji Q, Ji X, Ji X, Ji Y, Jiang H, Jiang X, Jiao J, Jiao Z, Jin S, Jin Y, Jing M, Johansson T, Kalantar-Nayestanaki N, Kang X, Kappert R, Kavatsyuk M, Ke B, Keshk I, Khoukaz A, Kiese P, Kiuchi R, Kliemt R, Koch L, Kolcu O, Kopf B, Kuemmel M, Kuessner M, Kupsc A, Kurth M, Kühn W, Lane J, Lange J, Larin P, Lavania A, Lavezzi L, Lei Z, Leithoff H, Lellmann M, Lenz T, Li C, Li C, Li C, Li D, Li F, Li G, Li H, Li H, Li H, Li H, Li H, Li J, Li J, Li J, Li K, Li L, Li L, Li P, Li S, Li W, Li W, Li X, Li X, Li X, Li Z, Liang H, Liang H, Liang H, Liang Y, Liang Y, Liao G, Liao L, Libby J, Limphirat A, Lin C, Lin D, Lin T, Liu B, Liu C, Liu D, Liu F, Liu F, Liu F, Liu G, Liu H, Liu H, Liu H, Liu J, Liu J, Liu J, Liu K, Liu K, Liu K, Liu L, Liu M, Liu P, Liu Q, Liu Q, Liu S, Liu T, Liu T, Liu W, Liu X, Liu Y, Liu Y, Liu Z, Liu Z, Lou X, Lu F, Lu H, Lu J, Lu J, Lu X, Lu Y, Lu Y, Luo C, Luo M, Luo P, Luo T, Luo X, Lyu X, Ma F, Ma H, Ma L, Ma M, Ma Q, Ma R, Ma R, Ma X, Ma X, Maas F, Maggiora M, Maldaner S, Malde S, Malik Q, Mangoni A, Mao Y, Mao Z, Marcello S, Meng Z, Messchendorp J, Mezzadri G, Min T, Mitchell R, Mo X, Muchnoi N, Muramatsu H, Nakhoul S, Nefedov Y, Nerling F, Nikolaev I, Ning Z, Nisar S, Olsen S, Ouyang Q, Pacetti S, Pan X, Pan Y, Pathak A, Pathak A, Patteri P, Pelizaeus M, Peng H, Peters K, Pettersson J, Ping J, Ping R, Plura S, Pogodin S, Poling R, Prasad V, Qi H, Qi H, Qi M, Qi T, Qian S, Qian W, Qian Z, Qiao C, Qin J, Qin L, Qin X, Qin X, Qin Z, Qiu J, Qu S, Rashid K, Ravindran K, Redmer C, Rivetti A, Rodin V, Rolo M, Rong G, Rosner C, Rump M, Sang H, Sarantsev A, Schelhaas Y, Schnier C, Schoenning K, Scodeggio M, Shan W, Shan X, Shangguan J, Shao M, Shen C, Shen H, Shen X, Shi H, Shi R, Shi X, Shi X, Song J, Song J, Song W, Song Y, Sosio S, Spataro S, Stieler F, Su K, Su P, Sui F, Sun G, Sun H, Sun J, Sun L, Sun S, Sun T, Sun W, Sun X, Sun Y, Sun Y, Sun Z, Tan Y, Tan Y, Tang C, Tang G, Tang J, Teng J, Thoren V, Tian W, Tian Y, Uman I, Wang B, Wang C, Wang D, Wang H, Wang H, Wang K, Wang L, Wang M, Wang M, Wang M, Wang S, Wang W, Wang W, Wang W, Wang X, Wang X, Wang X, Wang Y, Wang Y, Wang Y, Wang Y, Wang Y, Wang Z, Wang Z, Wang Z, Wang Z, Wei D, Weidner F, Wen S, White D, Wiedner U, Wilkinson G, Wolke M, Wollenberg L, Wu J, Wu L, Wu L, Wu X, Wu X, Wu Z, Xia L, Xiao H, Xiao S, Xiao Z, Xie X, Xie Y, Xie Y, Xing T, Xu C, Xu G, Xu Q, Xu W, Xu X, Xu Y, Yan F, Yan L, Yan W, Yan W, Yang H, Yang H, Yang L, Yang S, Yang Y, Yang Y, Yang Z, Ye M, Ye M, Yin J, You Z, Yu B, Yu C, Yu G, Yu J, Yu T, Yuan C, Yuan L, Yuan Y, Yuan Z, Yue C, Zafar A, Zeng XZ, Zeng Y, Zhang A, Zhang B, Zhang G, Zhang H, Zhang H, Zhang H, Zhang H, Zhang J, Zhang J, Zhang J, Zhang J, Zhang J, Zhang J, Zhang J, Zhang L, Zhang L, Zhang L, Zhang S, Zhang S, Zhang S, Zhang X, Zhang X, Zhang X, Zhang Y, Zhang Y, Zhang Y, Zhang Y, Zhang Y, Zhang Z, Zhao G, Zhao J, Zhao J, Zhao J, Zhao L, Zhao L, Zhao M, Zhao Q, Zhao S, Zhao Y, Zhao Y, Zhao Z, Zhemchugov A, Zheng B, Zheng J, Zheng Y, Zhong B, Zhong C, Zhou L, Zhou Q, Zhou X, Zhou X, Zhou X, Zhou X, Zhu A, Zhu J, Zhu K, Zhu K, Zhu S, Zhu T, Zhu W, Zhu W, Zhu Y, Zhu Z, Zou B, Zou J. Partial wave analysis of
J/ψ→γη′η′. Int J Clin Exp Med 2022. [DOI: 10.1103/physrevd.105.072002] [Citation(s) in RCA: 4] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022]
|
96
|
Ablikim M, Achasov MN, Adlarson P, Ahmed S, Albrecht M, Aliberti R, Amoroso A, An MR, An Q, Bai XH, Bai Y, Bakina O, Ferroli RB, Balossino I, Ban Y, Begzsuren K, Berger N, Bertani M, Bettoni D, Bianchi F, Bloms J, Bortone A, Boyko I, Briere RA, Cai H, Cai X, Calcaterra A, Cao GF, Cao N, Cetin SA, Chang JF, Chang WL, Chelkov G, Chen DY, Chen G, Chen HS, Chen ML, Chen SJ, Chen XR, Chen YB, Chen ZJ, Cheng WS, Cibinetto G, Cossio F, Cui XF, Dai HL, Dai JP, Dai XC, Dbeyssi A, de Boer RE, Dedovich D, Deng ZY, Denig A, Denysenko I, Destefanis M, De Mori F, Ding Y, Dong C, Dong J, Dong LY, Dong MY, Dong X, Du SX, Egorov P, Fan YL, Fang J, Fang SS, Fang Y, Farinelli R, Fava L, Feldbauer F, Felici G, Feng CQ, Feng JH, Fritsch M, Fu CD, Gao Y, Gao Y, Gao YG, Garzia I, Ge PT, Geng C, Gersabeck EM, Gilman A, Goetzen K, Gong L, Gong WX, Gradl W, Greco M, Gu LM, Gu MH, Guan CY, Guo AQ, Guo AQ, Guo LB, Guo RP, Guo YP, Guskov A, Han TT, Han WY, Hao XQ, Harris FA, He KK, He KL, Heinsius FH, Heinz CH, Heng YK, Herold C, Himmelreich M, Holtmann T, Hou GY, Hou YR, Hou ZL, Hu HM, Hu JF, Hu T, Hu Y, Huang GS, Huang LQ, Huang XT, Huang YP, Huang Z, Hussain T, Hüsken N, Andersson WI, Imoehl W, Irshad M, Jaeger S, Janchiv S, Ji Q, Ji QP, Ji XB, Ji XL, Ji YY, Jiang HB, Jiang XS, Jiao JB, Jiao Z, Jin S, Jin Y, Jing MQ, Johansson T, Kalantar-Nayestanaki N, Kang XS, Kappert R, Kavatsyuk M, Ke BC, Keshk IK, Khoukaz A, Kiese P, Kiuchi R, Kliemt R, Koch L, Kolcu OB, Kopf B, Kuemmel M, Kuessner M, Kupsc A, Kurth MG, Kühn W, Lane JJ, Lange JS, Larin P, Lavania A, Lavezzi L, Lei ZH, Leithoff H, Lellmann M, Lenz T, Li C, Li CH, Li C, Li DM, Li F, Li G, Li H, Li H, Li HB, Li HJ, Li HN, Li JL, Li JQ, Li JS, Li K, Li LK, Li L, Li PR, Li SY, Li WD, Li WG, Li XH, Li XL, Li X, Li ZY, Liang H, Liang H, Liang H, Liang YF, Liang YT, Liao GR, Liao LZ, Libby J, Limphirat A, Lin CX, Lin DX, Lin T, Liu BJ, Liu CX, Liu D, Liu FH, Liu F, Liu F, Liu GM, Liu HM, Liu H, Liu H, Liu JB, Liu JL, Liu JY, Liu K, Liu KY, Liu K, Liu L, Liu MH, Liu PL, Liu Q, Liu Q, Liu SB, Liu T, Liu T, Liu WM, Liu X, Liu Y, Liu YB, Liu ZA, Liu ZQ, Lou XC, Lu FX, Lu HJ, Lu JD, Lu JG, Lu XL, Lu Y, Lu YP, Luo CL, Luo MX, Luo PW, Luo T, Luo XL, Lyu XR, Ma FC, Ma HL, Ma LL, Ma MM, Ma QM, Ma RQ, Ma RT, Ma XX, Ma XY, Maas FE, Maggiora M, Maldaner S, Malde S, Malik QA, Mangoni A, Mao YJ, Mao ZP, Marcello S, Meng ZX, Messchendorp JG, Mezzadri G, Min TJ, Mitchell RE, Mo XH, Muchnoi NY, Muramatsu H, Nakhoul S, Nefedov Y, Nerling F, Nikolaev IB, Ning Z, Nisar S, Olsen SL, Ouyang Q, Pacetti S, Pan X, Pan Y, Pathak A, Pathak A, Patteri P, Pelizaeus M, Peng HP, Peters K, Pettersson J, Ping JL, Ping RG, Plura S, Pogodin S, Poling R, Prasad V, Qi H, Qi HR, Qi M, Qi TY, Qian S, Qian WB, Qian Z, Qiao CF, Qin JJ, Qin LQ, Qin XP, Qin XS, Qin ZH, Qiu JF, Qu SQ, Rashid KH, Ravindran K, Redmer CF, Rivetti A, Rodin V, Rolo M, Rong G, Rosner C, Rump M, Sang HS, Sarantsev A, Schelhaas Y, Schnier C, Schoenning K, Scodeggio M, Shan W, Shan XY, Shangguan JF, Shao M, Shen CP, Shen HF, Shen XY, Shi HC, Shi RS, Shi X, Shi XD, Song JJ, Song JJ, Song WM, Song YX, Sosio S, Spataro S, Stieler F, Su KX, Su PP, Sui FF, Sun GX, Sun HK, Sun JF, Sun L, Sun SS, Sun T, Sun WY, Sun X, Sun YJ, Sun YZ, Sun ZT, Tan YH, Tan YX, Tang CJ, Tang GY, Tang J, Teng JX, Thoren V, Tian WH, Tian YT, Uman I, Wang B, Wang CW, Wang DY, Wang HJ, Wang HP, Wang K, Wang LL, Wang M, Wang MZ, Wang M, Wang S, Wang W, Wang WH, Wang WP, Wang X, Wang XF, Wang XL, Wang Y, Wang YD, Wang YF, Wang YQ, Wang YY, Wang Z, Wang ZY, Wang Z, Wang Z, Wei DH, Weidner F, Wen SP, White DJ, Wiedner U, Wilkinson G, Wolke M, Wollenberg L, Wu JF, Wu LH, Wu LJ, Wu X, Wu XH, Wu Z, Xia L, Xiao H, Xiao SY, Xiao ZJ, Xie XH, Xie YG, Xie YH, Xing TY, Xu CJ, Xu GF, Xu QJ, Xu W, Xu XP, Xu YC, Yan F, Yan L, Yan WB, Yan WC, Yang HJ, Yang HX, Yang L, Yang SL, Yang YX, Yang Y, Yang Z, Ye M, Ye MH, Yin JH, You ZY, Yu BX, Yu CX, Yu G, Yu JS, Yu T, Yuan CZ, Yuan L, Yuan Y, Yuan ZY, Yue CX, Zafar AA, Zeng X, Zeng Y, Zhang AQ, Zhang BX, Zhang G, Zhang H, Zhang HH, Zhang HH, Zhang HY, Zhang JL, Zhang JQ, Zhang JW, Zhang JY, Zhang JZ, Zhang J, Zhang J, Zhang LM, Zhang LQ, Zhang L, Zhang S, Zhang SF, Zhang S, Zhang XD, Zhang XM, Zhang XY, Zhang Y, Zhang YT, Zhang YH, Zhang Y, Zhang Y, Zhang ZY, Zhao G, Zhao J, Zhao JY, Zhao JZ, Zhao L, Zhao L, Zhao MG, Zhao Q, Zhao SJ, Zhao YB, Zhao YX, Zhao ZG, Zhemchugov A, Zheng B, Zheng JP, Zheng YH, Zhong B, Zhong C, Zhou LP, Zhou Q, Zhou X, Zhou XK, Zhou XR, Zhou XY, Zhu AN, Zhu J, Zhu K, Zhu KJ, Zhu SH, Zhu TJ, Zhu WJ, Zhu WJ, Zhu YC, Zhu ZA, Zou BS, Zou JH. Observation of the Singly Cabibbo Suppressed Decay Λ_{c}^{+}→nπ^{+}. PHYSICAL REVIEW LETTERS 2022; 128:142001. [PMID: 35476477 DOI: 10.1103/physrevlett.128.142001] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 01/07/2022] [Revised: 02/05/2022] [Accepted: 03/01/2022] [Indexed: 06/14/2023]
Abstract
The singly Cabibbo-suppressed decay Λ_{c}^{+}→nπ^{+} is observed for the first time with a statistical significance of 7.3σ by using 3.9 fb^{-1} of e^{+}e^{-} collision data collected at center-of-mass energies between 4.612 and 4.699 GeV with the BESIII detector at BEPCII. The branching fraction of Λ_{c}^{+}→nπ^{+} is measured to be (6.6±1.2_{stat}±0.4_{syst})×10^{-4}. By taking the upper limit of branching fractions of Λ_{c}^{+}→pπ^{0} from the Belle experiment, the ratio of branching fractions between Λ_{c}^{+}→nπ^{+} and Λ_{c}^{+}→pπ^{0} is calculated to be larger than 7.2 at the 90% confidence level, which disagrees with most predictions of the available phenomenological models. In addition, the branching fractions of the Cabibbo-favored decays Λ_{c}^{+}→Λπ^{+} and Λ_{c}^{+}→Σ^{0}π^{+} are measured to be (1.31±0.08_{stat}±0.05_{syst})×10^{-2} and (1.22±0.08_{stat}±0.07_{syst})×10^{-2}, respectively, which are consistent with previous results.
Collapse
|
97
|
Islam MR, Ahmed S, Mostafa MG, Khan L, Alam MM, Alam A, Ahmed MB, Rahman MA. Predictors of Malignancy in Thyroid Nodules. Mymensingh Med J 2022; 31:372-378. [PMID: 35383753] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/14/2023]
Abstract
Thyroid swellings are common clinical problem throughout the world and also in Bangladesh. Most of thyroid swellings are multinodular, but a good percentage is solitary thyroid nodule. There is no robust, feasible method for malignancy differentiation has not been well established. The study evaluated thyroid nodules for risk of malignancy and compared history, clinical, sonographic features and FNAC findings with histopathology. This was a cross sectional study on 160 consecutive subjects of thyroid nodules done in the department of ENT and Head Neck Surgery of Mymensingh Medical College Hospital (MMCH), Mymensingh, Bangladesh during from July 2018 to December 2019. All patients were admitted and diagnosed by detail history, clinical examination, investigations and underwent thyroidectomy. Detailed history, clinical examination, ultrasonographic finding and FNAC variables were documented retrospectively and a mathematical model was established for malignancy prediction. In this study mean age of the patients of thyroid nodules was 37.54±11.49 years and majority of the patients were within 21-40 years of age. Frequency of thyroid nodules is more in female with male female ratio 1:7. Most of the thyroid nodules appeared in this study within 0-2 years (61.9%). In this series of thyroid nodules constituted 88.1% firm, 8.8% hard, 3.1% cystic. Among the patients 89(55.6%) cases have solitary thyroid nodule and 71(44.4%) cases have multinodular goitre Majority of the nodules were warm 57.5% followed by cold 42.5%. FNAC showed nodular goitre 72.5%, Follicular neoplasm 1.3%, Papillary carcinoma of thyroid 7.5%, colloid goitre 9.4%, suspicious papillary carcinoma 3.8% and lymphocytic thyroiditis 1.3%. In this study out of 85 solid nodule, 69(81.18%) were benign and 16(18.82%) was malignant and out of 3 cystic nodule 3(100%) were benign. In this study most of the benign and malignant nodules were predominantly solid. Study showed the malignancy is significantly (p=0.001) more in solid than cystic nodules. Final diagnosis in this study was done on the basis of histopathological reports. Out of 160 patients, histopathologically benign lesion was 120(75%) and malignant was 40(25%). Among malignant cases 36(22.5%) cases were papillary carcinoma, 1 case was medullary carcinoma and 3 cases were follicular carcinoma.
Collapse
|
98
|
Ahmed S, Prabahar AE, Saxena AK. Molecular docking-based interactions in QSAR studies on Mycobacterium tuberculosis ATP synthase inhibitors. SAR AND QSAR IN ENVIRONMENTAL RESEARCH 2022; 33:289-305. [PMID: 35532308 DOI: 10.1080/1062936x.2022.2066175] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 03/18/2022] [Accepted: 04/09/2022] [Indexed: 05/19/2023]
Abstract
Tuberculosis (TB) is a global threat with a large burden across the continents in terms of mortality, morbidity, and financial losses. The disease has evolved into multi-drug-resistant (MDR-TB) and extensively drug-resistant (XDR-TB) tuberculosis owing to numerous factors ranging from patients' non-compliance to demographical implications. There have been very few new drugs for resistant TB. Resistance has already been reported even for the newly introduced drug bedaquiline. An attempt has been made to integrate both structure-based and QSAR drug design techniques (QSAR-SBDD) for the identification of novel leads. The docking scores normally do not correlate with the activity. Hence, the docking results have been analysed in terms of the number of interactions rather than docking scores. The parameters derived from interactions have been used in developing the QSAR models. The best model shows a good correlation (r = 0.908) between the activity and interaction parameter 'C' describing the sum of all the interactions with each amino acid residue. This model also predicts external dataset with a good correlation (rext = 0.851) and can be used for the identification of novel chemical entities (NCEs) and repurposed drugs for TB therapeutics.
Collapse
|
99
|
Allorant A, Biswas S, Ahmed S, Wiens KE, LeGrand KE, Janko MM, Henry NJ, Dangel WJ, Watson A, Blacker BF, Kyu HH, Ross JM, Rahman MS, Hay SI, Reiner RC. Finding gaps in routine TB surveillance activities in Bangladesh. Int J Tuberc Lung Dis 2022; 26:356-362. [PMID: 35351241 PMCID: PMC8982646 DOI: 10.5588/ijtld.21.0624] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/02/2022] Open
Abstract
BACKGROUND : TB was the leading cause of death from a single infectious pathogen globally between 2014 and 2019. Fine-scale estimates of TB prevalence and case notifications can be combined to guide priority-setting for strengthening routine surveillance activities in high-burden countries. We produce policy-relevant estimates of the TB epidemic at the second administrative unit in Bangladesh. METHODS : We used a Bayesian spatial framework and the cross-sectional National TB Prevalence Survey from 2015–2016 in Bangladesh to estimate prevalence by district. We used case notifications to calculate prevalence-to-notification ratio, a key metric of under-diagnosis and under-reporting. RESULTS : TB prevalence rates were highest in the north-eastern districts and ranged from 160 cases per 100,000 (95% uncertainty interval [UI] 80–310) in Jashore to 840 (UI 690–1020) in Sunamganj. Despite moderate prevalence rates, the Rajshahi and Dhaka Divisions presented the highest prevalence-to-notification ratios due to low case notifications. Resolving subnational disparities in case detection could lead to 26,500 additional TB cases (UI 8,500–79,400) notified every year. CONCLUSION : This study is the first to produce and map subnational estimates of TB prevalence and prevalence-to-notification ratios, which are essential to target prevention and treatment efforts in high-burden settings. Reaching TB cases currently missing from care will be key to ending the TB epidemic.
Collapse
|
100
|
Wahid K, Ahmed S, He R, van Dijk L, Teuwen J, McDonald B, Salama V, Mohamed A, Salzillo T, Dede C, Taku N, Lai S, Fuller C, Naser M. Auto-Segmentation of Oropharyngeal Cancer Primary Tumors Using Multiparametric MRI-Based Deep Learning. Int J Radiat Oncol Biol Phys 2022. [DOI: 10.1016/j.ijrobp.2021.12.072] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|